Top Markets
Coin of the day
Aeglea BioTherapeutics, Inc. Aeglea BioTherapeutics, Inc.

Aeglea BioTherapeutics, Inc.

AGLE
Classement en actions #23495
Aeglea BioTherapeutics, Inc. is a clinical-stage biotechnology firm dedicated... Aeglea BioTherapeutics, Inc. is a clinical-stage biotechnology firm dedicated to creating human enzyme therapies for rare metabolic diseases. Their leading candidate, pegzilarginase, a recombinant human Arginase 1, is currently in the pivotal Phase III PEACE trial to assess its safety and effectiveness for treating Arginase 1 deficiency. Furthermore, the company is developing AGLE-177, a polyethylene glycol modified enzyme, which is progressing through Phase I/II clinical trials for homocystinuria. Their early-stage pipeline includes AGLE-325 for cystinuria, along with other ongoing research initiatives. Founded in 2013, the company was initially known as Aeglea BioTherapeutics Holdings, LLC, changing its name to Aeglea BioTherapeutics, Inc. in March 2015. It is based in Austin, Texas.
Prix de l'action
$19.30
Dernière synchronisation: 2023-12-26
Capitalisation boursière
$72.77M
Changement (1 jour)
6.22%
Changement (1 an)
0.00%
Pays
US
Échange Aeglea BioTherapeutics, Inc. (AGLE)

Catégorie

Historique du prix de l'action pour Aeglea BioTherapeutics, Inc. (AGLE)
Prix de clôture le plus élevé : $17.81 le 2023-12-01

Prix de clôture le plus bas : $240.00 le 2016-04-01
Historique du prix de l'action de Aeglea BioTherapeutics, Inc. de 2016 à 2026
Performance annuelle du prix de l'action
Année Performance
2023 80.43%
2022 -90.79%
2021 -48.55%
2020 6.06%
2019 3.25%
2018 49.19%
2017 -3.90%
2016 0.00%
Prix de l'action pour des entreprises similaires ou concurrentes
Entreprise Prix de l'action Variation 1a% Pays
$547.71 38.62%
US
$1.04K 58.06%
NL
$145.75 437.43%
US
$118.70 -15.60%
AU
$770.19 8.98%
CH